What's Happening?
Veritas Aortic Solutions, a company spun out from inQB8 Medical Technologies, has successfully raised $12 million in seed financing to advance its non-surgical treatment for aortic root and ascending aortic diseases.
The funding round was led by experienced MedTech angel investors, with significant participation from Cedars-Sinai Intellectual Property Company. The funds will be used to further develop the Veritas Transcatheter Valved Aortic Root Conduit (TVARC), which aims to provide a less invasive alternative to open-heart surgery for high-risk aortic conditions. The TVARC system is designed to seal off diseased parts of the aorta and restore healthy blood flow, potentially reducing the high mortality and morbidity rates associated with current surgical treatments.
Why It's Important?
The development of the Veritas TVARC system represents a significant advancement in the treatment of aortic diseases, which currently rely heavily on invasive surgical procedures. By offering a non-surgical alternative, Veritas Aortic Solutions could improve patient outcomes and reduce the risks associated with traditional open-heart surgeries. This innovation is particularly crucial given the high mortality rates linked to existing surgical options. The involvement of Cedars-Sinai and other investors underscores the potential impact of this technology on the healthcare industry, particularly in providing safer, more efficient treatment options for cardiovascular diseases.
What's Next?
With the secured funding, Veritas Aortic Solutions plans to continue the development of the TVARC system through First-in-Human clinical trials. The company aims to demonstrate the efficacy and safety of its technology, potentially paving the way for regulatory approval and broader adoption in the medical community. The success of these trials could lead to a significant shift in how aortic diseases are treated, offering patients a less invasive option with potentially better outcomes.
